{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:24Z","timestamp":1793064204898,"version":"4.5.0"},"reference-count":139,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bone disease represents a hallmark feature of multiple myeloma (MM), affecting nearly all patients during the disease course. Morphological imaging techniques play a crucial role in detecting bone disease, whereas functional ones are also fundamental for the differentiation of active from inactive disease and prognostic stratification. The International Myeloma Working Group (IMWG) currently recommends whole-body low-dose computed tomography (WBLDCT) as the first-choice imaging technique for the diagnosis of bone disease, whereas magnetic resonance imaging (MRI) is recommended in cases without further myeloma-defining events. However, 18F-fluorodeoxyglucose\u2013positron emission tomography\/CT (18F-FDG\u2013PET\/CT) currently represents the standard imaging technique, because it combines both morphological and functional data. Indeed, it allows detection of bone lesions (alternatively to WBLDCT), prognostic stratification, and monitoring of treatment response, being recommended by the IMWG for the assessment of imaging minimal residual disease. The IMPeTUs (Italian Myeloma criteria for PET Use) have proposed a visual descriptive assessment of 18F-FDG\u2013PET\/CT, with standardized definitions of metabolic responses. However, the use of further functional imaging techniques is being investigated, with diffusion-weighted (DW)\u2013MRI being related to very promising results regarding both staging and response assessment, to the extent that myeloma response assessment and diagnosis system guidelines have recently proposed a standardization of acquisition, interpretation and reporting of this technique in MM, and the British guidelines consider DW-MRI an alternative to 18F-FDG\u2013PET\/CT. This review summarizes current knowledge on the use of functional imaging techniques in MM and their incorporation in recommendations\/guidelines, and discusses potential future developments in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015686","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:21:19Z","timestamp":1756401679000},"page":"6252-6266","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"first","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"2Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3408-0461","authenticated-orcid":false,"given":"Marco","family":"Talarico","sequence":"additional","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"2Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"22","key":"2025122308361131400_bib1","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2025122308361131400_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2025122308361131400_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2025122308361131400_bib4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025122308361131400_bib5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025122308361131400_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2025122308361131400_bib7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2025122308361131400_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025122308361131400_bib9","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025122308361131400_bib10","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders [published correction appears in Lancet Oncol. 2019;20(7):e346]","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025122308361131400_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122308361131400_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"12","key":"2025122308361131400_bib13","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","article-title":"Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease","volume":"81","author":"Spinnato","year":"2012","journal-title":"Eur J Radiol"},{"issue":"1","key":"2025122308361131400_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"2025122308361131400_bib15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025122308361131400_bib16","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025122308361131400_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2025122308361131400_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2214\/AJR.10.4923","article-title":"A systematic review of the factors affecting accuracy of SUV measurements [published correction appears in Am J Roentgenol 2010;195(4):1043]","volume":"195","author":"Adams","year":"2010","journal-title":"Am J Roentgenol"},{"issue":"12","key":"2025122308361131400_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/metabo11120875","article-title":"Metabolic volume measurements in multiple myeloma","volume":"11","author":"Takahashi","year":"2021","journal-title":"Metabolites"},{"issue":"12","key":"2025122308361131400_bib20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J Nucl Med"},{"issue":"8","key":"2025122308361131400_bib21","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of total lesion glycolysis by 18F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma","volume":"23","author":"McDonald","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025122308361131400_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.16633","article-title":"Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography\/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice","volume":"191","author":"Terao","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2025122308361131400_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/RLU.0000000000003773","article-title":"Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET\/CT","volume":"46","author":"Terao","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2025122308361131400_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"2025122308361131400_bib25","doi-asserted-by":"crossref","first-page":"801792","DOI":"10.3389\/fnume.2022.801792","article-title":"Molecular imaging in multiple myeloma-novel PET radiotracers improve patient management and guide therapy","volume":"2","author":"von Hinten","year":"2022","journal-title":"Front Nucl Med"},{"key":"2025122308361131400_bib26","doi-asserted-by":"crossref","first-page":"100669","DOI":"10.1016\/j.jbo.2025.100669","article-title":"Diagnostic innovations: advances in imaging techniques for diagnosis and follow-up of multiple myeloma","volume":"51","author":"Talarico","year":"2025","journal-title":"J Bone Oncol"},{"issue":"5","key":"2025122308361131400_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2025122308361131400_bib28","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J"},{"issue":"23","key":"2025122308361131400_bib29","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2025122308361131400_bib30","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2025122308361131400_bib31","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review","volume":"118","author":"van Lammeren-Venema","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"2025122308361131400_bib32","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025122308361131400_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00256-010-1088-9","article-title":"The value of FDG PET\/CT in the initial staging and bone marrow involvement of patients with multiple myeloma","volume":"40","author":"Sager","year":"2011","journal-title":"Skeletal Radiol"},{"issue":"3","key":"2025122308361131400_bib34","first-page":"264","article-title":"Is whole body low dose CT still necessary in the era of 18F-FDG PET\/CT for the assessment of bone disease in multiple myeloma patients?","volume":"23","author":"Maggialetti","year":"2020","journal-title":"J Nucl Med"},{"issue":"4","key":"2025122308361131400_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2214\/AJR.08.1633","article-title":"Whole-body MRI versus PET in assessment of multiple myeloma disease activity","volume":"192","author":"Shortt","year":"2009","journal-title":"Am J Roentgenol"},{"issue":"4","key":"2025122308361131400_bib36","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00330-019-06469-1","article-title":"MRI versus 18F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance","volume":"30","author":"Lecouvet","year":"2020","journal-title":"Eur Radiol"},{"issue":"9","key":"2025122308361131400_bib37","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2025122308361131400_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2025122308361131400_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"31","author":"Han","year":"2021","journal-title":"Eur Radiol"},{"issue":"1","key":"2025122308361131400_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10238-023-01279-8","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"issue":"10","key":"2025122308361131400_bib41","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2025122308361131400_bib42","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025122308361131400_bib43","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/cancers12092532","article-title":"Glucose metabolism quantified by SUVmax on baseline FDG-PET\/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials","volume":"12","author":"Michaud-Robert","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025122308361131400_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","article-title":"18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System","volume":"46","author":"Jung","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2025122308361131400_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41408-021-00577-2","article-title":"Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET\/CT","volume":"11","author":"Cho","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025122308361131400_bib46","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00259-019-4275-5","article-title":"Pretreatment 18F-FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025122308361131400_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"key":"2025122308361131400_bib48","doi-asserted-by":"crossref","first-page":"668099","DOI":"10.3389\/fonc.2021.668099","article-title":"Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"2025122308361131400_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","article-title":"Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution","volume":"12","author":"Jim\u00e9nez-Segura","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025122308361131400_bib50","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2967\/jnumed.121.262884","article-title":"Molecular signature of 18F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study","volume":"63","author":"Alberge","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"2025122308361131400_bib51","doi-asserted-by":"crossref","first-page":"16429","DOI":"10.1038\/s41598-019-52740-2","article-title":"Proposal for a quantitative 18F-FDG PET\/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma","volume":"9","author":"Takahashi","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"2025122308361131400_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/bloodadvances.2023011890","article-title":"Analysis of baseline circulating tumor cells integrated with PET\/CT findings in transplant-ineligible multiple myeloma","volume":"8","author":"Ikeda","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2025122308361131400_bib53","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s00259-023-06339-5","article-title":"Application of an artificial intelligence-based tool in [18F]FDG PET\/CT for the assessment of bone marrow involvement in multiple myeloma","volume":"50","author":"Sachpekidis","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"2025122308361131400_bib54","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.18632\/oncotarget.2290","article-title":"18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation","volume":"5","author":"Lapa","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"2025122308361131400_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/10428194.2018.1459602","article-title":"Added prognostic value of FDG-PET\/CT in relapsing multiple myeloma patients","volume":"60","author":"Jamet","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2025122308361131400_bib56","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3390\/cancers13174323","article-title":"Prognostic value of FDG-PET\/CT parameters in patients with relapse\/refractory multiple myeloma before anti-CD38 based therapy","volume":"13","author":"Fouquet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025122308361131400_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12880-022-00788-4","article-title":"18F-FDG-PET\/CT in relapsed multiple myeloma: are prognostic thresholds different from first-line therapy?","volume":"22","author":"Zukovs","year":"2022","journal-title":"BMC Med Imaging"},{"issue":"suppl 1","key":"2025122308361131400_bib58","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2023-181235","article-title":"Outcomes of patients with extramedullary disease in triple-class exposed relapsed\/refractory multiple myeloma from the LocoMMotion + MoMMent studies","volume":"142","author":"Moreau","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2025122308361131400_bib59","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S2152-2650(23)01578-1","article-title":"OA-11 utility of 18FDG-PET\/CT for risk prediction in relapsed\/refractory multiple myeloma patients undergoing CAR-T cell therapy: analysis of baseline and early assessment scans after one and three months","volume":"23","author":"Tamariz-Amador","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2025122308361131400_bib60","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/blood-2024-206867","article-title":"Prognostic value of positron emission tomography\/computed tomography in multiple myeloma patients treated with Ide-Cel CAR-T cell therapy: preliminary results of a real-world IFM study from the Descar-T registry (CAR MY PET)","volume":"144","author":"Arnulf","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122308361131400_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2025122308361131400_bib62","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determine myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2025122308361131400_bib63","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/bloodadvances.2024014360","article-title":"Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma","volume":"9","author":"Zugasti","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2025122308361131400_bib64","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.jtct.2025.01.362","article-title":"Impact of extramedullary disease on survival outcomes in multiple myeloma patients treated with ciltacabtagene autoleucel and idecabtagene vicleucel: a comparative analysis","volume":"31","author":"Amoozgar","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025122308361131400_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000354839","article-title":"Positive correlation between baseline PET or PET\/CT findings and clinical parameters in multiple myeloma patients","volume":"131","author":"Park","year":"2014","journal-title":"Acta Haematol"},{"issue":"9","key":"2025122308361131400_bib66","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3390\/cancers12092399","article-title":"The link between cytogenetics\/genomics and imaging patterns of relapse and progression in patients with relapsed\/refractory multiple myeloma: a pilot study utilizing 18F-FDG PET\/CT","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025122308361131400_bib67","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","article-title":"The prognostic significance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)","volume":"11","author":"Sachpekidis","year":"2021","journal-title":"EJNMMI Res"},{"key":"2025122308361131400_bib68","doi-asserted-by":"crossref","first-page":"4198673","DOI":"10.1155\/2018\/4198673","article-title":"The role of 18F-FDG PET\/CT in multiple myeloma staging according to IMPeTUs: comparison of the Durie-Salmon Plus and other staging systems","volume":"2018","author":"Deng","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"2025122308361131400_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13550-024-01113-6","article-title":"Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [18F]FDG PET\/CT in patients with newly diagnosed multiple myeloma","volume":"14","author":"Marchiori","year":"2024","journal-title":"EJNMMI Res"},{"key":"2025122308361131400_bib70","doi-asserted-by":"crossref","first-page":"100598","DOI":"10.1016\/j.ejro.2024.100598","article-title":"IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma","volume":"13","author":"Xu","year":"2024","journal-title":"Eur J Radiol Open"},{"issue":"6","key":"2025122308361131400_bib71","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2025122308361131400_bib72","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 16","key":"2025122308361131400_bib73","doi-asserted-by":"crossref","first-page":"e20023","DOI":"10.1200\/JCO.2022.40.16_suppl.e20023","article-title":"Implications of 18F-FDG PET\/CT findings before autologous stem cell transplant in patients with multiple myeloma","volume":"40","author":"Khan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025122308361131400_bib74","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/1078-0432.CCR-18-0741","article-title":"Interim PET analysis in first-line therapy of multiple myeloma: prognostic value of \u0394SUVmax in the FDG-avid patients of the IMAJEM study","volume":"24","author":"Bailly","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025122308361131400_bib75","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"13","key":"2025122308361131400_bib76","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","article-title":"Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma","volume":"5","author":"Kaddoura","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2025122308361131400_bib77","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41375-023-01998-7","article-title":"Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation","volume":"37","author":"N\u00f8rgaard","year":"2023","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025122308361131400_bib78","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1182\/blood-2023-189047","article-title":"Pseudoprogression as adverse event of chimeric antigen receptor T cell therapy","volume":"142","author":"Schroeder","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025122308361131400_bib79","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1097\/RLU.0000000000004588","article-title":"2-[18F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma","volume":"48","author":"Jamet","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2025122308361131400_bib80","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025122308361131400_bib81","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2025122308361131400_bib89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"suppl 1","key":"2025122308361131400_bib82","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025122308361131400_bib83","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2025122308361131400_bib84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2025122308361131400_bib85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-023-00856-0","article-title":"Correction: integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025122308361131400_bib86","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2024-210171","article-title":"MRD by flow cytometry and FDG-PET\/CT for the post-induction response assessment in patients with multiple myeloma treated in the phase 3 GMMG HD7 study","volume":"144","author":"Hajiyianni","year":"2024","journal-title":"Blood"},{"key":"2025122308361131400_bib87","author":"Bansal","year":"2023"},{"issue":"suppl 1","key":"2025122308361131400_bib88","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2023-180896","article-title":"Sequential imaging with diffusion-weighted whole-body MRI (DW-MRI) and PET-CT identifies patients at high risk of relapse in multiple myeloma","volume":"142","author":"Schinke","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025122308361131400_bib90","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2011.08658.x","article-title":"Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology","volume":"153","author":"Hillengass","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122308361131400_bib91","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40644-020-0286-5","article-title":"Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI","volume":"20","author":"Almeida","year":"2020","journal-title":"Cancer Imaging"},{"issue":"4","key":"2025122308361131400_bib120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13244-016-0492-7","article-title":"MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings","volume":"7","author":"Dutoit","year":"2016","journal-title":"Insights Imaging"},{"issue":"4","key":"2025122308361131400_bib139","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1148\/rg.2019180096","article-title":"Whole-body imaging of multiple myeloma: diagnostic criteria","volume":"39","author":"Ormond Filho","year":"2019","journal-title":"Radiographics"},{"issue":"1","key":"2025122308361131400_bib92","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/jcm13010264","article-title":"Imaging of multiple myeloma: present and future","volume":"13","author":"Rodr\u00edguez-Laval","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"2025122308361131400_bib93","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.14401","article-title":"Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response","volume":"176","author":"Latifoltojar","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2025122308361131400_bib94","doi-asserted-by":"crossref","first-page":"e0229607","DOI":"10.1371\/journal.pone.0229607","article-title":"Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI","volume":"15","author":"Takasu","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"2025122308361131400_bib95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13244-022-01253-0","article-title":"Implementation of whole-body MRI (MY-RADS) within the OPTIMUM\/MUKnine multi-centre clinical trial for patients with myeloma","volume":"13","author":"Rata","year":"2022","journal-title":"Insights Imaging"},{"issue":"17","key":"2025122308361131400_bib96","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"2025122308361131400_bib97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00256-022-04119-0","article-title":"Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis","volume":"52","author":"Torkian","year":"2023","journal-title":"Skeletal Radiol"},{"issue":"5","key":"2025122308361131400_bib98","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/diagnostics11050857","article-title":"Whole body low dose computed tomography (WBLDCT) can be comparable to whole-body magnetic resonance imaging (WBMRI) in the assessment of multiple myeloma","volume":"11","author":"Ippolito","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"2025122308361131400_bib99","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"12","key":"2025122308361131400_bib100","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00277-020-04265-2","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma","volume":"99","author":"Mesguich","year":"2020","journal-title":"Ann Hematol"},{"issue":"8","key":"2025122308361131400_bib101","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","article-title":"Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma","volume":"48","author":"Westerland","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2025122308361131400_bib102","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"issue":"suppl 2","key":"2025122308361131400_bib103","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S2152-2650(24)01855-X","article-title":"OA-14 prospective functional bone disease evaluation of newly diagnosed multiple myeloma with combined use of (18)F-FDG-PET\/CT and whole-body diffusion weighted magnetic resonance","volume":"24","author":"Talarico","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025122308361131400_bib104","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3324\/haematol.2015.124115","article-title":"A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma","volume":"100","author":"Mai","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2025122308361131400_bib105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025122308361131400_bib106","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1007\/s00330-021-07687-2","article-title":"Total diffusion volume in MRI vs. total lesion glycolysis in PET\/CT for tumor volume evaluation of multiple myeloma","volume":"31","author":"Terao","year":"2021","journal-title":"Eur Radiol"},{"issue":"2","key":"2025122308361131400_bib107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3892\/etm.2021.10259","article-title":"Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma","volume":"22","author":"Costachescu","year":"2021","journal-title":"Exp Ther Med"},{"key":"2025122308361131400_bib108","doi-asserted-by":"crossref","first-page":"780078","DOI":"10.3389\/fonc.2022.780078","article-title":"The apparent diffusion coefficient of diffusion-weighted whole-body magnetic resonance imaging affects the survival of multiple myeloma independently","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"2025122308361131400_bib109","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2025122308361131400_bib110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiol.13131529","article-title":"Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma","volume":"271","author":"Giles","year":"2014","journal-title":"Radiology"},{"issue":"7","key":"2025122308361131400_bib111","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.acra.2017.12.008","article-title":"Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study","volume":"25","author":"Wu","year":"2018","journal-title":"Acad Radiol"},{"issue":"1","key":"2025122308361131400_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1148\/radiol.211388","article-title":"Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma","volume":"304","author":"Koutoulidis","year":"2022","journal-title":"Radiology"},{"issue":"suppl 1","key":"2025122308361131400_bib113","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2024-199873","article-title":"Total diffusion volume evaluated by whole-body diffusion weighted magnetic resonance image for the assessment of tumor burden in multiple myeloma; relations with measurable residual disease evaluated by next-generation flow cytometry and bone marrow CD138 staining assessed by Qupath","volume":"144","author":"Narita","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025122308361131400_bib114","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis","volume":"218","author":"Rama","year":"2022","journal-title":"Am J Roentgenol"},{"issue":"9","key":"2025122308361131400_bib115","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1002\/ajh.26995","article-title":"Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma","volume":"98","author":"Belotti","year":"2023","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025122308361131400_bib116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2024-198779","article-title":"Early identification of functional high risk multiple myeloma patients after transplant with diffusion-weighted whole-body MRI: predictive role of fat fraction in addition to RAC score","volume":"144","author":"Belotti","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025122308361131400_bib117","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/cancers13081938","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body MRI with diffusion-weighted imaging in the evaluation of treatment response of multiple myeloma patients eligible for autologous stem cell transplant","volume":"13","author":"Mesguich","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025122308361131400_bib118","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","volume":"198","author":"B\u00f6ckle","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122308361131400_bib119","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jmri.20349","article-title":"Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers","volume":"22","author":"Nos\u00e0s-Garcia","year":"2005","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"2025122308361131400_bib121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40644-024-00740-5","article-title":"DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI\/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET\/MRI imaging approach","volume":"24","author":"Jamet","year":"2024","journal-title":"Cancer Imaging"},{"issue":"1","key":"2025122308361131400_bib122","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.14038","article-title":"Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma","volume":"174","author":"Hillengass","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122308361131400_bib123","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-14-1029","article-title":"Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma","volume":"21","author":"Merz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2 Pt 1","key":"2025122308361131400_bib124","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1078-0432.CCR-06-0061","article-title":"Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma","volume":"13","author":"Hillengass","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025122308361131400_bib125","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00330-015-3928-4","article-title":"Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study","volume":"26","author":"Merz","year":"2016","journal-title":"Eur Radiol"},{"issue":"9","key":"2025122308361131400_bib126","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ejrad.2013.04.012","article-title":"Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma","volume":"82","author":"Dutoit","year":"2013","journal-title":"Eur J Radiol"},{"issue":"2","key":"2025122308361131400_bib127","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejrad.2015.11.040","article-title":"Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma","volume":"85","author":"Dutoit","year":"2016","journal-title":"Eur J Radiol"},{"issue":"2","key":"2025122308361131400_bib128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1148\/radiol.09090629","article-title":"Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging","volume":"254","author":"Lin","year":"2010","journal-title":"Radiology"},{"issue":"4","key":"2025122308361131400_bib129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.berh.2012.07.008","article-title":"Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure","volume":"26","author":"Bernstein","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"2025122308361131400_bib130","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00330-021-08388-6","article-title":"Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma","volume":"32","author":"Burns","year":"2022","journal-title":"Eur Radiol"},{"issue":"9","key":"2025122308361131400_bib131","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results","volume":"33","author":"Jamet","year":"2023","journal-title":"Eur Radiol"},{"issue":"2","key":"2025122308361131400_bib132","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2022.2142053","article-title":"Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET\/MRI","volume":"64","author":"Baril\u00e0","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2025122308361131400_bib133","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2025122308361131400_bib134","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/cancers14030606","article-title":"Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025122308361131400_bib135","doi-asserted-by":"crossref","first-page":"874847","DOI":"10.3389\/fmed.2022.874847","article-title":"Application of 18F-FDG PET-CT images based radiomics in identifying vertebral multiple myeloma and bone metastases","volume":"9","author":"Jin","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2025122308361131400_bib136","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/RLI.0000000000000986","article-title":"Prediction of bone marrow biopsy results from MRI in multiple myeloma patients using deep learning and radiomics","volume":"58","author":"Wennmann","year":"2023","journal-title":"Invest Radiol"},{"issue":"21","key":"2025122308361131400_bib137","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.3390\/diagnostics13213372","article-title":"Current status and future of artificial intelligence in MM imaging: a systematic review","volume":"13","author":"Alipour","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"2025122308361131400_bib138","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00259-024-06711-z","article-title":"Artificial intelligence-based application in multiple myeloma","volume":"51","author":"Piscopo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6252\/2474194\/blooda_adv-2024-015686-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6252\/2474194\/blooda_adv-2024-015686-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:36:33Z","timestamp":1766496993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6252\/546994\/Fifteen-years-of-use-of-functional-imaging-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":139,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015686","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,10]]}}}